Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-10-09

AUTHORS

Kaoru Takase, Shigeru Ohno, Haruko Ideguchi, Eiichi Uchio, Mitsuhiro Takeno, Yoshiaki Ishigatsubo

ABSTRACT

Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behçet’s disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. We here report successful switching from infliximab to adalimumab in a BD patient. Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to cyclosporine until the patient had experienced repeated infliximab-related infusion reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab. More... »

PAGES

243-245

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00296-009-1178-y

DOI

http://dx.doi.org/10.1007/s00296-009-1178-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046011907

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19816689


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adalimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Behcet Syndrome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Hypersensitivity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infliximab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takase", 
        "givenName": "Kaoru", 
        "id": "sg:person.0756602733.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756602733.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohno", 
        "givenName": "Shigeru", 
        "id": "sg:person.013722512012.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722512012.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ideguchi", 
        "givenName": "Haruko", 
        "id": "sg:person.01324761473.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324761473.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uchio", 
        "givenName": "Eiichi", 
        "id": "sg:person.01161260361.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161260361.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takeno", 
        "givenName": "Mitsuhiro", 
        "id": "sg:person.01027461256.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027461256.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.eye.6702352", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022745504", 
          "https://doi.org/10.1038/sj.eye.6702352"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2005.40647.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049457966", 
          "https://doi.org/10.1111/j.1572-0241.2005.40647.x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-10-09", 
    "datePublishedReg": "2009-10-09", 
    "description": "Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Beh\u00e7et\u2019s disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. We here report successful switching from infliximab to adalimumab in a BD patient. Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to cyclosporine until the patient had experienced repeated infliximab-related infusion reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00296-009-1178-y", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1093123", 
        "issn": [
          "0172-8172", 
          "1437-160X"
        ], 
        "name": "Rheumatology International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "Beh\u00e7et's disease", 
      "clinical remission", 
      "Beh\u00e7et\u2019s disease-related uveitis", 
      "infliximab treatment", 
      "ocular attacks", 
      "infusion reactions", 
      "ocular lesions", 
      "hypersensitivity reactions", 
      "BD patients", 
      "patients", 
      "infliximab", 
      "effective option", 
      "uveitis", 
      "discontinuation", 
      "remission", 
      "disease", 
      "treatment", 
      "adalimumab", 
      "therapy", 
      "lesions", 
      "hypersensitivity", 
      "options", 
      "agents", 
      "successful switching", 
      "remarkable effect", 
      "effect", 
      "experience", 
      "reaction", 
      "attacks", 
      "way", 
      "switching", 
      "refractory ocular lesions", 
      "infliximab-allergic patient", 
      "severe Beh\u00e7et disease-related uveitis", 
      "disease-related uveitis"
    ], 
    "name": "Successful switching to adalimumab in an infliximab-allergic patient with severe Beh\u00e7et disease-related uveitis", 
    "pagination": "243-245", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046011907"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00296-009-1178-y"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19816689"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00296-009-1178-y", 
      "https://app.dimensions.ai/details/publication/pub.1046011907"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_491.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00296-009-1178-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00296-009-1178-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00296-009-1178-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00296-009-1178-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00296-009-1178-y'


 

This table displays all metadata directly associated to this object as RDF triples.

193 TRIPLES      22 PREDICATES      75 URIs      65 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00296-009-1178-y schema:about N0787046d54384d4f98b83f6abe324b80
2 N149560b0d36144198dea28222b7f160d
3 N1b9e8b3a8c4d4fd18fbdc65bd45d5359
4 N2dfd3219e3824201b900db1582ad9b04
5 N3405a6a30c814f39bc6d97765b84cd61
6 N474a0c28cc2a4204b97cd8c2e9883cf2
7 N74c16636701445dfbb699427197ef24d
8 N9874165e1639460e83adccaddde06e16
9 N9dd91318444b4ee690ac527b8a711549
10 N9dffe9cee3e34e1bbda0128ad91d99ce
11 Nc9e51217022e4cf9ad510f4046c54d27
12 Nebc06541325740d98cb02da0d04b883c
13 anzsrc-for:11
14 anzsrc-for:1103
15 schema:author Nb122e82c0ddb48bfb9fd4bcd512f68b0
16 schema:citation sg:pub.10.1038/sj.eye.6702352
17 sg:pub.10.1111/j.1572-0241.2005.40647.x
18 schema:datePublished 2009-10-09
19 schema:datePublishedReg 2009-10-09
20 schema:description Infliximab has demonstrated remarkable effects on controlling uveitis in patients with Behçet’s disease (BD). However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions. We here report successful switching from infliximab to adalimumab in a BD patient. Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to cyclosporine until the patient had experienced repeated infliximab-related infusion reactions. Discontinuation of the therapy led to another ocular attacks immediately. Switching to adalimumab induced clinical remission again. Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab.
21 schema:genre article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N6bfb7bebee1343029140deb4711eb87d
25 Nbb0d926802c24bb8a453124c82ad8e70
26 sg:journal.1093123
27 schema:keywords BD patients
28 Behçet's disease
29 Behçet’s disease-related uveitis
30 adalimumab
31 agents
32 attacks
33 clinical remission
34 discontinuation
35 disease
36 disease-related uveitis
37 effect
38 effective option
39 experience
40 hypersensitivity
41 hypersensitivity reactions
42 infliximab
43 infliximab treatment
44 infliximab-allergic patient
45 infusion reactions
46 lesions
47 ocular attacks
48 ocular lesions
49 options
50 patients
51 reaction
52 refractory ocular lesions
53 remarkable effect
54 remission
55 severe Behçet disease-related uveitis
56 successful switching
57 switching
58 therapy
59 treatment
60 uveitis
61 way
62 schema:name Successful switching to adalimumab in an infliximab-allergic patient with severe Behçet disease-related uveitis
63 schema:pagination 243-245
64 schema:productId N33eb065c79c84d73b196949fcee87b1d
65 N6e17a64b69174e008bb974637b1bd2a5
66 N854c328c392a4c06b2a95465fb71a8d1
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046011907
68 https://doi.org/10.1007/s00296-009-1178-y
69 schema:sdDatePublished 2021-12-01T19:22
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N9a9998ad6c0d404c8a2d0bd4b54dcc40
72 schema:url https://doi.org/10.1007/s00296-009-1178-y
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N0787046d54384d4f98b83f6abe324b80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Drug Hypersensitivity
78 rdf:type schema:DefinedTerm
79 N131f09ec5893446da45668cd94d812b1 rdf:first sg:person.01125133646.44
80 rdf:rest rdf:nil
81 N149560b0d36144198dea28222b7f160d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
82 schema:name Adalimumab
83 rdf:type schema:DefinedTerm
84 N1b9e8b3a8c4d4fd18fbdc65bd45d5359 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Severity of Illness Index
86 rdf:type schema:DefinedTerm
87 N2512981155424c20b14e43b25a689833 rdf:first sg:person.013722512012.55
88 rdf:rest N5edb9ba635654a24a8740efd9f81320d
89 N2dfd3219e3824201b900db1582ad9b04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Infliximab
91 rdf:type schema:DefinedTerm
92 N33eb065c79c84d73b196949fcee87b1d schema:name dimensions_id
93 schema:value pub.1046011907
94 rdf:type schema:PropertyValue
95 N3405a6a30c814f39bc6d97765b84cd61 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Female
97 rdf:type schema:DefinedTerm
98 N474a0c28cc2a4204b97cd8c2e9883cf2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Antibodies, Monoclonal, Humanized
100 rdf:type schema:DefinedTerm
101 N5edb9ba635654a24a8740efd9f81320d rdf:first sg:person.01324761473.79
102 rdf:rest Nd8f308fa7694473dab2c3ccce8b0ed37
103 N6bfb7bebee1343029140deb4711eb87d schema:issueNumber 2
104 rdf:type schema:PublicationIssue
105 N6e17a64b69174e008bb974637b1bd2a5 schema:name doi
106 schema:value 10.1007/s00296-009-1178-y
107 rdf:type schema:PropertyValue
108 N74c16636701445dfbb699427197ef24d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Behcet Syndrome
110 rdf:type schema:DefinedTerm
111 N854c328c392a4c06b2a95465fb71a8d1 schema:name pubmed_id
112 schema:value 19816689
113 rdf:type schema:PropertyValue
114 N9874165e1639460e83adccaddde06e16 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Antibodies, Monoclonal
116 rdf:type schema:DefinedTerm
117 N9a9998ad6c0d404c8a2d0bd4b54dcc40 schema:name Springer Nature - SN SciGraph project
118 rdf:type schema:Organization
119 N9dd91318444b4ee690ac527b8a711549 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Humans
121 rdf:type schema:DefinedTerm
122 N9dffe9cee3e34e1bbda0128ad91d99ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Adult
124 rdf:type schema:DefinedTerm
125 Nb122e82c0ddb48bfb9fd4bcd512f68b0 rdf:first sg:person.0756602733.05
126 rdf:rest N2512981155424c20b14e43b25a689833
127 Nb844f9a28c0748e9a06f8cb69fbcbfec rdf:first sg:person.01027461256.90
128 rdf:rest N131f09ec5893446da45668cd94d812b1
129 Nbb0d926802c24bb8a453124c82ad8e70 schema:volumeNumber 31
130 rdf:type schema:PublicationVolume
131 Nc9e51217022e4cf9ad510f4046c54d27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Antirheumatic Agents
133 rdf:type schema:DefinedTerm
134 Nd8f308fa7694473dab2c3ccce8b0ed37 rdf:first sg:person.01161260361.51
135 rdf:rest Nb844f9a28c0748e9a06f8cb69fbcbfec
136 Nebc06541325740d98cb02da0d04b883c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Treatment Outcome
138 rdf:type schema:DefinedTerm
139 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
140 schema:name Medical and Health Sciences
141 rdf:type schema:DefinedTerm
142 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
143 schema:name Clinical Sciences
144 rdf:type schema:DefinedTerm
145 sg:journal.1093123 schema:issn 0172-8172
146 1437-160X
147 schema:name Rheumatology International
148 schema:publisher Springer Nature
149 rdf:type schema:Periodical
150 sg:person.01027461256.90 schema:affiliation grid-institutes:grid.268441.d
151 schema:familyName Takeno
152 schema:givenName Mitsuhiro
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01027461256.90
154 rdf:type schema:Person
155 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
156 schema:familyName Ishigatsubo
157 schema:givenName Yoshiaki
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
159 rdf:type schema:Person
160 sg:person.01161260361.51 schema:affiliation grid-institutes:grid.413045.7
161 schema:familyName Uchio
162 schema:givenName Eiichi
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01161260361.51
164 rdf:type schema:Person
165 sg:person.01324761473.79 schema:affiliation grid-institutes:grid.413045.7
166 schema:familyName Ideguchi
167 schema:givenName Haruko
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324761473.79
169 rdf:type schema:Person
170 sg:person.013722512012.55 schema:affiliation grid-institutes:grid.413045.7
171 schema:familyName Ohno
172 schema:givenName Shigeru
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013722512012.55
174 rdf:type schema:Person
175 sg:person.0756602733.05 schema:affiliation grid-institutes:grid.413045.7
176 schema:familyName Takase
177 schema:givenName Kaoru
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756602733.05
179 rdf:type schema:Person
180 sg:pub.10.1038/sj.eye.6702352 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022745504
181 https://doi.org/10.1038/sj.eye.6702352
182 rdf:type schema:CreativeWork
183 sg:pub.10.1111/j.1572-0241.2005.40647.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049457966
184 https://doi.org/10.1111/j.1572-0241.2005.40647.x
185 rdf:type schema:CreativeWork
186 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
187 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
188 rdf:type schema:Organization
189 grid-institutes:grid.413045.7 schema:alternateName Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan
190 Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan
191 schema:name Center for Rheumatic Diseases, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, 232-0024, Yokohama, Kanagawa, Japan
192 Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan
193 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...